Key result
Admission HALP score fails to predict mortality or in-hospital outcomes in acute heart failure.
Why the study?
The hemoglobin-albumin-lymphocyte-platelet (HALP) score has been proposed as a prognostic marker in acute heart failure, but external validation is limited.
Does the admission HALP score predict in-hospital mortality, prolonged hospital stay, all-cause mortality, and heart-failure rehospitalization in patients hospitalized with acute heart failure?
Cohort (n=197)
No
Does the admission HALP score predict in-hospital mortality, prolonged hospital stay, all-cause mortality, and heart-failure rehospitalization in patients hospitalized with acute heart failure?
In this external validation cohort of acute heart failure patients, the admission HALP score failed to predict in-hospital or long-term clinical outcomes once cutoff-optimization bias was removed, outclassed by established risk scores like EHMRG and MAGGIC.
Answers are grounded in this paper and cite their sources.
Admission HALP score lacks prognostic value in acute heart failure; challenges prior reports and leaves validation to prospective studies.
Background The hemoglobin–albumin–lymphocyte–platelet (HALP) score integrates nutritional, inflammatory, and hematologic status and has been proposed as a prognostic marker in acute heart failure (AHF), but external validation is limited. Methods We retrospectively analyzed 197 consecutive patients hospitalized with AHF at a tertiary center. HALP was calculated at admission, and the pre-specified outcomes were in-hospital mortality, prolonged hospital stay (>7 days), all-cause mortality over follow-up, and heart-failure rehospitalization. Discrimination was assessed by the area under the receiver-operating-characteristic curve (AUC) with DeLong 95% confidence intervals (CIs), and associations were tested with crude and age/sex-adjusted logistic regression (in-hospital outcomes) and Cox regression (mortality over follow-up), using both data-derived (Youden) and pre-specified HALP thresholds. Results The cohort had a median age of 71 years (30.5% female) and a median follow-up of 15.5 months; in-hospital mortality was 12.7%, prolonged stay 19.4%, and all-cause mortality 31.0%. HALP did not discriminate any outcome (AUC 0.53 [95% CI 0.41–0.65] for in-hospital mortality, 0.47 [0.36–0.59] for prolonged stay, and 0.57 [0.48–0.66] for all-cause mortality; all CIs included 0.50). A Youden-optimized threshold appeared associated with mortality in logistic regression (adjusted odds ratio 2.02, 95% CI 1.02–4.00), but the signal vanished under pre-specified thresholds (median-split adjusted odds ratio 1.23, 0.67–2.28) and in time-to-event analysis (adjusted hazard ratio per 1-SD decrease 1.04, 0.78-1.38; Youden threshold 1.75, 0.97-3.16; log-rank across quartiles p = 0.15). In the same patients, the established EHMRG and MAGGIC scores discriminated mortality (AUC 0.71 and 0.65; CIs excluding 0.50), whereas HALP correlated only with severity markers (NYHA class rho = −0.31; NT-proBNP rho = −0.16; CRP rho = −0.17). Conclusion In this independent cohort, HALP reflected disease severity but did not predict outcomes once cutoff-optimization bias was removed, and should not be used as a stand-alone risk-stratification tool in AHF.
No takes yet. Share an insight, caveat, or question.
Aydın et al. (2026) conducted a cohort in Acute heart failure (AHF) (n=197). Admission hemoglobin–albumin–lymphocyte–platelet (HALP) score (per 1-SD decrease, pre-specified median ≤28.4, or lowest quartile ≤16.9) vs. Higher HALP score (>28.4) and established risk scores (EHMRG and MAGGIC) was evaluated on All-cause mortality over follow-up (time-to-event analysis per 1-SD decrease in HALP) (Adjusted HR 1.04, 95% CI 0.78-1.38, p=0.78). The admission HALP score did not discriminate or predict all-cause mortality (AUC 0.57; adjusted HR per 1-SD decrease 1.04, 95% CI 0.78-1.38) or in-hospital outcomes in acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: